3E63
Fragment based discovery of JAK-2 inhibitors
Summary for 3E63
Entry DOI | 10.2210/pdb3e63/pdb |
Related | 3E62 3E64 |
Descriptor | Tyrosine-protein kinase JAK2, 5-phenyl-1H-indazol-3-amine (3 entities in total) |
Functional Keywords | drug discovery, jak2, fragment based, atp-binding, disease mutation, kinase, membrane, nucleotide-binding, phosphoprotein, proto-oncogene, sh2 domain, transferase, tyrosine-protein kinase |
Biological source | Homo sapiens (human) |
Cellular location | Endomembrane system; Peripheral membrane protein (By similarity): O60674 |
Total number of polymer chains | 1 |
Total formula weight | 34887.74 |
Authors | Antonysamy, S.,Fang, W.,Hirst, G.,Park, F.,Russell, M.,Smyth, L.,Sprengeler, P.,Stappenbeck, F.,Steensma, R.,Thompson, D.A.,Wilson, M.,Wong, M.,Zhang, A.,Zhang, F. (deposition date: 2008-08-14, release date: 2008-10-14, Last modification date: 2012-02-08) |
Primary citation | Antonysamy, S.,Hirst, G.,Park, F.,Sprengeler, P.,Stappenbeck, F.,Steensma, R.,Wilson, M.,Wong, M. Fragment-based discovery of JAK-2 inhibitors. Bioorg.Med.Chem.Lett., 19:279-282, 2009 Cited by PubMed Abstract: Fragment-based hit identification coupled with crystallographically enabled structure-based drug design was used to design potent inhibitors of JAK-2. After two iterations from fragment 1, we were able to increase potency by greater than 500-fold to provide sulfonamide 13, a 78-nM JAK-2 inhibitor. PubMed: 19019674DOI: 10.1016/j.bmcl.2008.08.064 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.9 Å) |
Structure validation
Download full validation report